Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 28, 2005

Automation of biochip array technology for quality results

Roisin M. Molloy, Robert I. Mc Connell, John V. Lamont and Stephen P. FitzGerald

Abstract

Background: Proteomics' requirement for simultaneous measurement of multiple markers is now possible with biochip array technology. Many laboratories utilise in-house, manual procedures for biochip fabrication and sample testing. Reproducibility and standardisation of biochip processes is vital to ensure quality of results and offer the best tool for elucidation of complex relationships between multiple proteins in diseased conditions.

Methods: Various novel control checks have been implemented in biochip fabrication, reagent manufacture, automation and imaging processes for the Evidence analyser. Reference spots enable location of discrete test regions on the surface of the biochip and simultaneous quantification of multiple markers. Performance and standardisation methods are presented.

Results: Formulation of dispense solution for discrete test regions had a direct effect on their shape, stability and integrity on the biochip surface. Assays for fertility hormones and drugs of abuse demonstrated excellent precision, stability and comparison with other commercial methods.

Conclusion: Control processes employed in the manufacture and analysis of Evidence components ensure reproducibility of assays for a range of routine and novel markers.


Corresponding author: Mr. John Lamont, 55 Diamond Road, Crumlin, Co Antrim, BT29 4QY, UK Phone: +44 2894 422413, Fax: +44 2894 452912, All authors are employees of Randox Laboratories Ltd, Crumlin, UK, and were involved in the development of the Evidence Biochip Array analyser.

References

1. Ramsay G. DNA chips: state-of-the-art. Nat Biotechnol 1998; 16:40–4.10.1038/nbt0198-40Search in Google Scholar

2. Tillib SV, Mirzabekov AD. Advances in the analysis of DNA sequence variations using oligonucleotide microchip technology. Curr Opin Biotechnol 2001; 12:53–8.10.1016/S0958-1669(00)00168-3Search in Google Scholar

3. Simone NL, Paweletz CP, Charboneau L, Petricoin EF III, Liotta LA. Laser capture microdissesction: beyond functional genomics to proteomics. Mol Diag 2000; 5:301–7.10.2165/00066982-200005040-00008Search in Google Scholar

4. Brower V. Proteomics: biology in the post-genomic era. Eur Mol Biol Org Reports 2001; 2:558–60.10.1093/embo-reports/kve144Search in Google Scholar

5. Tomlinson IM, Holt LJ. Protein profiling comes of age. Genome Biol 2001; 2.10.1186/gb-2001-2-2-reviews1004Search in Google Scholar

6. Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, et al. An approach to proteomic analysis of human tumours. Mol Carcinog 2000; 27:158–65.10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2Search in Google Scholar

7. Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 1999; 96:12589–94.10.1073/pnas.96.22.12589Search in Google Scholar

8. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. CancerRes 1999; 59:3003–9.Search in Google Scholar

9. Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: detection, quantitation and characterization of lactoferrin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun 1998; 245:764–73.10.1006/bbrc.1998.8466Search in Google Scholar

10. Bruenner BA, Yip TT, Hutchens TW. Quantitative analysis of oligonucleotides by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 1996; 10:1797–801.10.1002/(SICI)1097-0231(199611)10:14<1797::AID-RCM754>3.0.CO;2-5Search in Google Scholar

11. Kodadek T. Microarrays, prospects and problems. Chem Biol 2001; 8:105–15.10.1016/S1074-5521(00)90067-XSearch in Google Scholar

12. Abbott A. Betting on tomorrow's chips. Nature 2002; 415:112–4.10.1038/415112aSearch in Google Scholar

13. Cahill DJ. Protein and antibody arrays and their medical applications. J Immunol Methods 2001; 250:81–91.10.1016/S0022-1759(01)00325-8Search in Google Scholar

14. Edwards AM, Arrowsmith CH, des Pallieres B. Proteomics: new tools for a new era. Modern Drug Discovery 2000; 5:35–44.Search in Google Scholar

15. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572–7.10.1016/S0140-6736(02)07746-2Search in Google Scholar

16. Jenkins RE, Pennington SR. Arrays for protein expression profiling: towards a viable alternative to two-dimensional gel electrophoresis? Proteomics 2001; 1:13–29.10.1002/1615-9861(200101)1:1<13::AID-PROT13>3.0.CO;2-JSearch in Google Scholar

17. Wilson D, Nock S. Recent developments in protein Microarray technology. Angew Chem Int End 2003; 42:494–500.10.1002/anie.200390150Search in Google Scholar

18. Kusnezow W, Hoheisel JD. Antibody arrays: promises and problems. Bio Techniques 2002; 33:S14–S23.10.2144/dec02kusnezowSearch in Google Scholar

19. FitzGerald SP, Lamont J, Mc Connell RI, ElBenchikh O. Development of a high throughput automated analyser using biochip array technology. Clin Chem 2005; 51:1165–76.10.1373/clinchem.2005.049429Search in Google Scholar

20. Ekins R, Chu F. Immunoassay and other ligand assays: present status and future trends. JIFCC 1997; 9:100–9.Search in Google Scholar

21. Diehl F, Grahlmann, Beier M, Hoheisel JD. Manufacturing DNA microarrays of high spot homogeneity and reduced background signal. Nucleic Acids Res 2001; 29:E38.10.1093/nar/29.7.e38Search in Google Scholar

Received: 2005-9-20
Accepted: 2005-10-26
Published Online: 2005-11-28
Published in Print: 2005-12-1

©2005 by Walter de Gruyter Berlin New York